Syndax plummets as IPF asset axatilimab fails in phase 2 trial (SNDX:NASDAQ)
Syndax Pharmaceuticals (SNDX) fell 15% in after-hours trading after its drug axatilimab failed to meet the primary endpoint in a phase 2 trial for idiopathic pulmonary fibrosis. The trial aimed to reduce the rate of decline in forced vital capacity.
How this was made
The 30-second read
Why it matters
The failure underscores the high risk of late‑stage biotech trials and may trigger portfolio rebalancing among investors.
Market read
The news is a primary disclosure of a negative Phase‑2 result, likely to cause a short‑term price decline.
What to watch
Potential for a fast‑track IND filing for a different disease could mitigate the downside.
Background
Syndax Pharmaceuticals (NASDAQ:SNDX) focuses on oncology and fibrosis therapies. Axatilimab was its lead candidate for idiopathic pulmonary fibrosis.
Ticker impact
Syndax reported its IPF drug axatilimab failed its Phase 2 primary endpoint, causing a ~15% after‑hours drop.
downward pressure as the market prices in the negative trial outcome
Phase‑2 failure is material for a biotech; no mitigating data was disclosed, so the stock is likely to continue falling.
Market effects
May weigh on other IPF or fibrosis biotech peers as investors scrutinize trial pipelines.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond the niche biotech space.
Counterpoint
If the company can pivot the asset to another indication, the drop could be over‑reacted.
Key entities
- companySyndax Pharmaceuticals
Biotech firm developing axatilimab for IPF.
